Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. (2020)
Attributed to:
Warwick Integrative Synthetic Biology Centre
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41416-019-0681-5
PubMed Identifier: 31844184
Publication URI: http://europepmc.org/abstract/MED/31844184
Type: Journal Article/Review
Volume: 122
Parent Publication: British journal of cancer
Issue: 4
ISSN: 0007-0920